Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 5Unknown 3Completed 3Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 49Immunoglobulin Light-chain Amyloidosis 6Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Neoplasm, Residual 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Myelodysplastic Syndromes 2Lymphoma 2Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Autoimmune Diseases of the Nervous System 1Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1Anemia, Aplastic 1Amyloidosis 1Acute Kidney Injury 1

Interventions

Dexamethasone 5Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Lenalidomide 3Ciprofloxacin 3Bortezomib 3pomalidomide 2fludarabine phosphate 2fludarabine 2elotuzumab 2carfilzomib 2Radiotherapy 2Immunoglobulins, Intravenous 2Cyclophosphamide 2Amoxicillin-Potassium Clavulanate Combination 2siltuximab 1selinexor 1nirogacestat 1iberdomide 1daratumumab 1belantamab mafodotin 1Positron-Emission Tomography 1Melphalan 1Interviews as Topic 1Immunoglobulins 1Focus Groups 1Fecal Microbiota Transplantation 1Clonal Hematopoiesis 1Clavulanic Acid 1Chromatin Immunoprecipitation Sequencing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms, Plasma Cell × daratumumab × Clear all
NCT07075510 2025-10-29

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

University of Maryland, Baltimore

Phase 1/2 Recruiting
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡